Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type I.
- 1 April 1986
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 83 (8), 2672-2676
- https://doi.org/10.1073/pnas.83.8.2672
Abstract
We report the production and characterization of a human monoclonal antibody reactive against the major envelope glycoprotein of human T-cell leukemia virus type I (HTLV-I), a virus linked to the etiology of adult T-cell leukemia. We exposed lymph-node cells derived from a patient with adult T-cell leukemia to the Epstein-Barr virus in vitro and obtained a B-cell clone (designated 0.5 .alpha.) by a limiting dilution technique. The secreted product of 0.5 .alpha. is a monoclonal antibody (also designated 0.5 .alpha.; that is IgG1 and has K light chains) that binds to the cell membrane of T-cells infected with HTLV-I and lyses them in the presence of complement. The antibody does not react with HTLV-I negative T cells. In electroblot assays, the monoclonal antibody detects a 46-kDa glycoprotein in disrupted HTLV-I virions and a 34-kDa product following digestion of the viral protein with endoglycosidase F. These molecules have been reported to represent the HTLV-I env gene products. The antibody does not react with HTLV-II and HTLV-III virions. Glycoproteins of 61 and 68 kDa, which are known to be encoded at least in part by the env gene of HTLV-I, are precipitated by the antibody from endogenously radiolabeled HTLV-I-infected HUT 102-B2 and MT-2 cells, respectively. These results suggest that this human monoclonal antibody reacts with an env-encoded glycoprotein of HTLV-I. By using a competition assay with a biotin-labeled 0.5.alpha. antibody, we observed that 15 out of 15 patients with adult T-cell leukemia had antibodies that block binding of the 0.5.alpha. antibody to HTLV-I virions. This suggests that the antigen detected by 0.5.alpha. antibody is a common epitope recognized in HTLV-I-infected individuals in vivo. This antibody, as well as the general strategy for making human monoclonal antibodies reactive against pathogenic retroviruses, may have diagnostic or therapeutic application.This publication has 28 references indexed in Scilit:
- Monoclonal Idiotope Vaccine Against Streptococcus pneumoniae InfectionScience, 1984
- Functional Properties of Antigen-Specific T Cells Infected by Human T-Cell Leukemia-Lymphoma Virus (HTLV-I)Science, 1984
- Sequence of the Envelope Glycoprotein Gene of Type II Human T Lymphotropic VirusScience, 1984
- Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)Science, 1983
- Isolation and Transmission of Human Retrovirus (Human T-Cell Leukemia Virus)Science, 1983
- Detection of the human T cell lymphoma virus p19 in cells of some patients with cutaneous T cell lymphoma and leukemia using a monoclonal antibody.The Journal of Experimental Medicine, 1981
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences, 1980
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Proceedings of the National Academy of Sciences, 1979
- EB virus-induced B lymphocyte cell lines producing specific antibodyNature, 1977
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970